

For
INTENSIVE *Vitamin Therapy*

In manifest vitamin deficiencies it is inadvisable and impractical to rely primarily on dietary correction. The deprivation of essential nutrient factors usually has existed for many years, and it is important to give adequate treatment in order to restore health promptly.

Pluraxin is especially designed for intensive vitamin therapy.

SPECIAL THERAPEUTIC FORMULA

Vitamin A (from fish liver oil)	25,000 U.S.P. Units
Vitamin B ₁ (thiamine)	15 mg.
Vitamin B ₂ (riboflavin)	10 mg.
Vitamin B ₆ (pyridoxine)	2 mg.
Nicotinamide	150 mg.
Folic acid	5 mg.
Calcium pantothenate	10 mg.
Vitamin C (ascorbic acid)	150 mg.
Vitamin D ₂ (calciferol)	1000 U.S.P. Units

Pluraxin[®]

WITH FOLIC ACID


High Potency - Therapeutic Formula -
Multiple Vitamin Capsules

One capsule of Pluraxin daily is usually sufficient. Some patients may require larger doses during the early stages of treatment. In vitamin therapy, "it is far better to prescribe too much than too little, too soon rather than too late" (Spies). Available in bottles of 30 and 100 capsules; same formula also supplied without folic acid, in bottles of 30 and 100 capsules.

PLURAXIN, trademark
reg. U.S. & Canada



Winthrop-Stearns INC.
NEW YORK 13, N. Y. WINDSOR, ONT.



BLOOD

The Journal of Hematology

NOTE TO CONTRIBUTORS

Papers are accepted for publication on condition that they are contributed solely to this journal. Manuscripts must be typewritten, double or triple spaced, on good quality bond paper with at least one inch margins, and the original copy submitted. References to literature should be made in conformance with American Medical Association usage. Tables should be as brief as possible. Charts and illustrations in black and white will be furnished without charge, unless submitted in excessive numbers. The excess in cost of colored illustrations must be borne by the contributors. University and hospital affiliations of each author, and an address for mailing proofs, should be submitted with the article.

Reprints of articles will be furnished to contributors when ordered in advance. A label showing cost of reprints, with an order, is sent with proofs. BLOOD—The Journal of Hematology is published monthly.

Correspondence concerning business matters should be addressed to Grunc & Stratton, Inc., Medical Publishers, 381 4th Ave., New York 16, N. Y. All communications concerning editorial matters should be addressed to Dr. William Dameshek, 30 Bennet St., Boston 11, Mass.

Subscription rates, \$12.00 per year within the United States; foreign, \$13.00 per year. Single copies \$2.00, foreign \$2.50.

Agents for Great Britain: H. K. Lewis & Co., Ltd., 136, Gower Street, London, W.C.1.

Published monthly at Mount Royal & Guilford Avenues, Baltimore, Md. Entered as second-class matter January 2, 1946, at the Post Office at Baltimore, Maryland, under the Act of March 3, 1879.

PAPERS TO APPEAR IN EARLY ISSUES

ANTIBODIES IN CHRONIC LEUKEMIA, *by* Dudley Merrill.

CASE REPORT: MONOCYTIC LEUKEMIA, *by* Carl J. Gessler.

THE PRESENT POSITION IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA, *by* A. Pincus.

THE EFFECT OF URETHANE ON THE NUCLEAR MORPHOLOGY OF CELLS OF THE GRANULOCYTE SERIES AS OBSERVED IN MARROW CULTURES AND LEUKEMIC BLOOD, *by* Edwin E. Osgood and I. T. Chu.

THE USE OF URETHANE (ETHYL CARBAMATE) IN THE TREATMENT OF LEUKEMIA: A PRELIMINARY REPORT, *by* Charles H. Watkins, Talbert Cooper and Herbert Z. Giffin.

IS IT POSSIBLE TO TRANSMIT OR ACCELERATE THE DEVELOPMENT OF MOUSE LEUKEMIA BY TISSUE EXTRACTS, *by* J. Engelbreth-Holm.

INFECTIOUS MONONUCLEOSIS, *by* Sir Henry Tidy.

THE SIGNIFICANCE OF MEGAKARYOCYTES IN THE PERIPHERAL CIRCULATION, *by* Sir Lionel Whitby.

CHRONIC INFECTIOUS MONONUCLEOSIS, *by* Raphael Issacs.

THE ACTIVE PRINCIPLE IN THE LEUKOCYTOSIS-PROMOTING FACTOR OF EXUDATES, *by* Valy Menkin.

THE POSSIBILITY OF PRECIPITATING THE LEUKEMIC STATE BY EMOTIONAL FACTORS, *by* F. R. Miller and H. W. Jones.

THE PATHOLOGY OF INFECTIOUS MONONUCLEOSIS, *by* R. Philip Custer and Edward B. Smith.

URETHANE THERAPY IN LEUKEMIA, *by* Adolph J. Creskoff, Thomas Fitz-Hugh, Jr., and John W. Frost.

FOLLICULAR LYMPHOBLASTOMA, *by* Ovid O. Meyer.


This One



YU82-Q11-GK85

**A NEW TECHNICON
microslide cabinet for**

flat-filing



As slides are freshly completed they are put at once into these compartmented flat-filing trays. The slides are then handled, filed, and dried in the same tray: they need never be removed except for microscopic examination. Slides do not contact each other, drying is speedier, cover glasses stay put.

Complete visibility. Each specimen, with its identification data, stands out boldly against the neutral gray background of the tray floor . . . a great convenience in the storage, distribution, and return-checking of reference collections in classroom work.

Large capacity. Fifty drawers in each cabinet, with sixteen or thirty-two slides to the drawer. All-steel construction throughout, like all other Technicon "LAB-AID" microslide files.

Fresh slides go directly from laboratory-to-microscopist-to-file, always in the same light-weight metal tray. Cabinet units are small enough to fit easily on desk, and can be stacked with existing "LAB-AID" vertical slide-files.



TECHNICON

Lab-aid

**flat-filing
microslide cabinet**

THE TECHNICON COMPANY
215 East 149th St., New York 51, N. Y.

Send me particulars of "LAB-AID" flat-filing cabinets.

Name _____

Address _____

City _____ State _____